Biotech Values

[rph_in_wi]

Re: local formulations of CA4P.

I agree with Dew that these questions are definitely important factors for the long-term use of CA4P.

Localized formulations of ophthalmic medications are not always the answer to eliminating cardiac effects. There are a number of currently available ophthalmics that are absorbed into the systemic circulation and cause significant clinical effects, even at low doses. An example would be Timoptic, a betablocker used for glaucoma, that can cause significant slowing of the heart rate.

Also, in the past 10 years, I have seen numerous medications get pulled off the market due to a newly found cardiac side effect. The fact that they have an idea about some QT elongation should cause the FDA to, in the least, force more study of these effects. IMO, this could delay/hold any approval.

RPH